Millennium Management
CNTA

Millennium Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Millennium Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.74M Buy
+69,000
New +$1.76M ﹤0.01% 3558
2025
Q4 		– Sell
-50,000
Closed -$1.21M – 6065
2025
Q3 		$1.21M Buy
+50,000
New +$889K ﹤0.01% 4479

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Millennium Management's CNTA Position: Q1 2026 in Review

Millennium Management reduced its Centessa Pharmaceuticals (CNTA) stake by 61% in Q1 2026, selling an estimated $29.4M and leaving 722,121 shares worth $28.7M. The position accounts for 0.01% of the portfolio, ranked #1268.

Millennium Management first reported a position in CNTA in Q2 2021 and has held it in 12 quarters since. The position peaked at $46.8M in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Millennium Management held 722,121 shares of Centessa Pharmaceuticals worth $28.7M as of Q1 2026.
  • Millennium Management sold 1,148,550 Centessa Pharmaceuticals shares in Q1 2026, an estimated $29.4M.
  • Centessa Pharmaceuticals made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1268 holding.
  • Millennium Management first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 12 quarters since.
  • Millennium Management's Centessa Pharmaceuticals position peaked at $46.8M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.